The Technical Field "ポリペプチド" had 16 patent application filings in the most recent period (2023-01-01 to 2023-02-28). This is a significantly decreased of -219 filings (-93.2%) over 235 they had in the same period of the previous year (2022-01-01 to 2022-02-28). This report also includes technical terms related to " ポリペプタイド " in the search set.
The highest number of filings in 2016 with 2,125 cases, and their lowest number in 2022 with 1,317 cases.
The mean of the number of filings over the last 5 years (2018 to 2023, 8,609 cases in total) is 1,435, and the median is 1,648. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
Index | Value |
---|---|
Average | 1,435 patents |
Std Dev | 656 |
COV | 0.5 |
The number of filings has been decreasing for the last 3 years (2020 to 2023).
Year | Cases | YOY |
---|---|---|
2022 year | 1,317 cases | -24.79 % |
2021 year | 1,751 cases | +13.26 % |
2020 year | 1,546 cases | -20.88 % |
This report provides the latest patent analysis information (the IP landscape, including a patent map) on the patent search results of the JP patent database for ポリペプチド for the period of the last 10 years (2014-01-01 to 2024-10-31). You can compare the information in this report with the trends in your competitors’ patent filings and technologies, and use it to search for important patents.
This service provides, free of charge, a patent analysis report based on the latest patent data (Japanese, U.S., European, and PCT application publications) for use in patent searches, patent analysis, and IP landscaping. The service is offered by "Patent Integration" a firm specializing in patent search/patent analysis.
This report includes basic information to help you understand the IP strategy and management of ポリペプチド, such as changes in the number of patents/patent applications they have filed, comparisons of the numbers of patents/patent applications filed by their peers and competitors, their top coapplicants (joint research partners, alliance partners), and their most important patents. It can be used in various intellectual property business operations such as IP landscaping, patent search/patent analysis, preparation of intellectual property business evaluation reports, selection of M&A candidates, and selection of alliance partners.
He is a patent attorney at a patent office. He specializes in invention counseling, patent filing, and intellectual property strategies for start-up companies and new businesses in the fields of software, information technology and artificial intelligence. He runs a patent course for beginners on Udemy, an online course provider.
After studying physics at the University of Tokyo as a doctoral student, he was engaged in intellectual property analysis and technology trend research as an in-house patent attorney at a precision equipment manufacturer and at Toyota Central R&D Labs. Inc..
The concept of the "IP landscape" (IPL) has been attracting attention recently.
An IP landscape is not limited to patent information, but also integrates and analyzes business information (e.g., non-patent information such as papers, news releases, stock information, and market information). Intellectual-property-based business management is realized through the analysis of intellectual property information applied to the formulation of management strategies and business strategies. This is a comprehensive approach that includes but not limited to planning of open and closed strategies, selecting M&A candidates, searching for alliance partners, and formulating intellectual property strategies, through the exploitation of intellectual property information.
IP landscaping usually includes patent search and patent analysis. In patent search and patent analysis, it is important to grasp the market position of each company and the overall technological trends and development trends for each technology. More specifically, it is important to understand what intellectual property your own company and other companies hold, what the strengths and weaknesses of other companies are, and how other companies are trying to exploit their intellectual property. In other words, it is important to understand both the business strategy and the intellectual property strategy of each company.
After reading this search report, you may be interested in more detailed patent searches and patent analysis. We offer a service called Patent Integration, which is an integrated patent search and patent analysis service. With reasonable pricing and a simple user interface such that even beginners can quickly search for and analyze patent information by company or technology from a web browser, please consider using it for detailed patent searches, patent analysis, and IP landscaping.
Patent Integration has a patent-landscaping function that can visually represent a set of tens of thousands of patents/patent applications. This allows you to convincingly show the technical positions of your company and its competitors to your management and business strategists in order to formulate management strategies and business strategies.
The changes in the number of patent filings of ポリペプチド over the last 20 years (JP) are shown below.
The change in the number of patents/patent applications is the most basic index in patent analysis. By examining the change in the number of patents/patent applications, you can see the status of technological development and R&D focus for each company or technology. It should be noted that since there is a one and a half year lag between the filing and the laying open of patent applications, it is not possible to analyze the situation more recently than one and half years prior to the present.
In this report, you can only see the change in the number of patents/patent applications by company or technology, whereas Patent Integration allows you to quickly compare the number of patent applications with your competitors in each technical field by cross-referencing with other keywords and patent classifications.
This patent analysis report was created for a patent search set of 16,610 cases retrieved by applying the following search formula and analysis period to the following patent database. Patent information such as a patent analysis result, a patent map, and a patent landscape can be freely used for patent searches, analysis, and work on intellectual property strategies, including IP landscaping.
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as ポリペプチド are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Comparing the number of applications of each company, リジェネロン・ファーマシューティカルズ・インコーポレイテッド has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 32 cases, followed by ザリージェンツオブザユニバーシティオブカリフォルニア with 17 cases.
Name | Cases |
---|---|
リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 32 cases |
ザリージェンツオブザユニバーシティオブカリフォルニア | 17 cases |
エフホフマン-ラロシュアーゲー | 9 cases |
ジェネンテックインコーポレイテッド | 7 cases |
中外製薬株式会社 | 7 cases |
ノバルティスアーゲー | 6 cases |
アムジエン・インコーポレーテツド | 4 cases |
Comparing the number of applications of each company, ジェネンテックインコーポレイテッド has the highest number of joint applications in the last for the target period (2014 to 2024) with 263 cases, followed by ザリージェンツオブザユニバーシティオブカリフォルニア with 216 cases.
Name | Cases |
---|---|
ジェネンテックインコーポレイテッド | 263 cases |
ザリージェンツオブザユニバーシティオブカリフォルニア | 216 cases |
エフホフマン-ラロシュアーゲー | 205 cases |
ノバルティスアーゲー | 198 cases |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 196 cases |
アムジエン・インコーポレーテツド | 146 cases |
中外製薬株式会社 | 132 cases |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 6 cases |
ノバルティスバクシンズアンドダイアグノスティックスインコーポレーテッド | 5 cases |
ヒューマンジノームサイエンシーズインコーポレイテッド | 1 cases |
Below is a patent map showing changes in the number of applications for JP patents of 11 companies in the same industry over the past 20 years.
The number of patents and changes in the number of patents of other companies (competitors) in the same industry as ポリペプチド are shown below.
Comparison of changes in the number of patents with peers and competitors is an important analytical index for understanding the intellectual property strategies of each company. By checking the transition of the number of patents for each company / competitor, you can check the status of focus on technology development and R&D for each company / technology.
It should be noted that patents have a time lag of one and a half years from filing to publication, so it is not possible to analyze the situation more recent than one and a half years.
If you want to find out more information, " Patent Integration , You can compare the number of patent applications with competitors in each technical field in a short time by multiplying with other keywords and patent classifications.Please use it for more detailed patent information analysis such as selection of M&A candidate destinations and alliance destinations.
Among the top coapplicants, ザリージェンツオブザユニバーシティオブカリフォルニア has the highest number of joint applications in the last in the last 3 years (2022 to 2024) with 17 cases, followed by エフホフマン-ラロシュアーゲー with 9 cases.
Name | Cases |
---|---|
ザリージェンツオブザユニバーシティオブカリフォルニア | 17 cases |
エフホフマン-ラロシュアーゲー | 9 cases |
ジェネンテックインコーポレイテッド | 7 cases |
ノバルティスアーゲー | 6 cases |
アムジエン・インコーポレーテツド | 4 cases |
Among the top coapplicants, ジェネンテックインコーポレイテッド has the highest number of joint applications in the last for the target period (2014 to 2024) with 263 cases, followed by ザリージェンツオブザユニバーシティオブカリフォルニア with 216 cases.
Name | Cases |
---|---|
ジェネンテックインコーポレイテッド | 263 cases |
ザリージェンツオブザユニバーシティオブカリフォルニア | 216 cases |
エフホフマン-ラロシュアーゲー | 205 cases |
ノバルティスアーゲー | 198 cases |
アムジエン・インコーポレーテツド | 146 cases |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 6 cases |
ヒューマンジノームサイエンシーズインコーポレイテッド | 1 cases |
Below is a ranking of the number of JP patent applications by ポリペプチド’s top 7 coapplicants over the last 20 years.
Below is a patent map showing the changes in the numbers of JP patent filings by ポリペプチド’s top 7 coapplicants over the last 20 years.
ポリペプチド filed 263 joint applications with ジェネンテックインコーポレイテッド for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 76 cases in total) is 12.7, and the median is 13.0. The coefficient of variation (standard deviation/mean) is 0.6, and there have been relatively large fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2015 with 61 cases, and their lowest number in 2022 with 7 cases.
Index | Value |
---|---|
Average | 12.7 patents |
Std Dev | 7.7 |
COV | 0.6 |
Year | Cases | YOY |
---|---|---|
2022 year | 7 cases | -66.7 % |
2021 year | 21 cases | +75.0 % |
2020 year | 12 cases | -14.29 % |
ポリペプチド filed 216 joint applications with ザリージェンツオブザユニバーシティオブカリフォルニア for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 125 cases in total) is 20.8, and the median is 22.5. The coefficient of variation (standard deviation/mean) is 0.5, and there have been big fluctuations in the number of filings from year to year.
The highest number of filings in 2018 with 35 cases, and their lowest number in 2015 with 10 cases.
Index | Value |
---|---|
Average | 20.8 patents |
Std Dev | 10.9 |
COV | 0.5 |
Year | Cases | YOY |
---|---|---|
2022 year | 17 cases | -26.09 % |
2021 year | 23 cases | -17.86 % |
2020 year | 28 cases | +27.27 % |
ポリペプチド filed 198 joint applications with ノバルティスアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 61 cases in total) is 10.2, and the median is 10.5. The coefficient of variation (standard deviation/mean) is 0.6, and there have been relatively large fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2015 with 51 cases, and their lowest number in 2022 with 6 cases.
Index | Value |
---|---|
Average | 10.2 patents |
Std Dev | 6.3 |
COV | 0.6 |
Year | Cases | YOY |
---|---|---|
2022 year | 6 cases | -57.1 % |
2021 year | 14 cases | +55.6 % |
2020 year | 9 cases | -25.00 % |
ポリペプチド filed 205 joint applications with エフホフマン-ラロシュアーゲー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 5 years (2018 to 2023, 72 cases in total) is 12.0, and the median is 11.0. The coefficient of variation (standard deviation/mean) is 0.6, and there have been relatively large fluctuations in the number of filings from year to year.
The number of filings has been decreasing for the last 3 years (2020 to 2023). The highest number of filings in 2015 with 47 cases, and their lowest number in 2022 with 9 cases.
Index | Value |
---|---|
Average | 12.0 patents |
Std Dev | 7.4 |
COV | 0.6 |
Year | Cases | YOY |
---|---|---|
2022 year | 9 cases | -30.8 % |
2021 year | 13 cases | +44.4 % |
2020 year | 9 cases | -47.1 % |
ポリペプチド filed 6 joint applications with グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー for the analysis period (2014 to 2024).
The mean of the number of filings over the last 10 years (2013 to 2023, 7 cases in total) is 0.6, and the median is 0. The coefficient of variation (standard deviation/mean) is 1.5, and there have been very big fluctuations in the number of filings from year to year.
The highest number of filings in 2014 with 3 cases, and their lowest number in 2022 with 0 cases.
Index | Value |
---|---|
Average | 0.6 patents |
Std Dev | 1.0 |
COV | 1.5 |
Year | Cases | YOY |
---|---|---|
2019 year | 1 cases | - |
2018 year | 0 cases | - |
2017 year | 0 cases | - |
The following shows JP patents held by ポリペプチド that have had an invalidation trial against them demanded or an opposition filed against them by a third party, and ポリペプチド’s JP patents/patent applications of high importance cited by Examiners in patent examination processes.
By noting the most important patents, you can obtain knowledge of the competitive business environment in which ポリペプチド is placed (e.g., whether it is a fiercely competitive environment or an oligopolistic market and the like). In general, it can be understood that a company with a large number of demands for invalidation trials is developing their business in a business environment where IP disputes are common.
If you want to search for more detailed information, you can use Patent Integration to retrieve and download by company cited patents/patent applications or patents undergoing invalidation trials. You can quickly extract important patents from a patent set that includes multiple competitors by cross-referencing with other keywords and patent classifications. Please consider using it for searches for important patents/patent applications.
In the last 3 years (2021-11-01 ~ 2024-10-31), there were 4 patents Invalidation Trial from third parties. The average number of Invalidation Trial is 1.0 times. The most recently Invalidation Trial patent is 特許7016341 "PD-1軸結合アンタゴニスト及びTIGIT阻害剤を使用するがんの治療方法" (Invalidation Trial day 2023-03-27) , next is 特許6278598 "細胞傷害誘導治療剤" (Invalidation Trial day 2022-03-31) .
- | No. | Title | Invalidation Trial days |
---|---|---|---|
1 | 特許7016341 | PD-1軸結合アンタゴニスト及びTIGIT阻害剤を使用するがんの治療方法 | 2023-03-27 |
2 | 特許6278598 | 細胞傷害誘導治療剤 | 2022-03-31 |
3 | 特許6773929 | 細胞傷害誘導治療剤 | 2022-03-31 |
4 | 特許6692856 | RNA依存性標的DNA修飾およびRNA依存性転写調節のための方法および組成物 | 2022-02-25 |
In the last 3 years (2021-11-01 ~ 2024-10-31), there were 7 patents Opposition from third parties. The average number of Opposition is 1.0 times. The most recently Opposition patent is 特許7420330 "アレルギーの抗原およびそのエピトープ" (Opposition day 2024-07-10) , next is 特許7448953 "眼疾患のための細胞モデル及び治療関連出願への相互参照" (Opposition day 2024-04-17) .
- | No. | Title | Opposition days |
---|---|---|---|
1 | 特許7420330 | アレルギーの抗原およびそのエピトープ | 2024-07-10 |
2 | 特許7448953 | 眼疾患のための細胞モデル及び治療関連出願への相互参照 | 2024-04-17 |
3 | 特許7305630 | N-アセチルノイラミン酸の発酵生産 | 2024-01-09 |
4 | 特許7237544 | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 | 2023-09-11 |
5 | 特許7210036 | アルツハイマー病および他の神経変性障害のためのバイオマーカーおよび診断方法 | 2023-07-20 |
6 | 特許7168454 | 固体表面のスパイダーシルクコーティング | 2023-05-08 |
7 | 特許6881813 | 核酸ワクチン | 2021-11-30 |
In the last 3 years (2021-11-01 ~ 2024-10-31), there were 20 patents Protest from third parties. The average number of Protest is 1.1 times. The most recently Protest patent is 特表2023-506785 "炭酸アルコール飲料" (Protest day 2024-03-15) , next is 特開2021-143156 "シャンプー組成物" (Protest day 2024-03-15) .
- | No. | Title | Protest days |
---|---|---|---|
1 | 特表2023-506785 | 炭酸アルコール飲料 | 2024-03-15 |
2 | 特開2021-143156 | シャンプー組成物 | 2024-03-15 |
3 | 特表2022-546204 | 苦味受容体ブロッカー及びその同定方法 | 2024-02-22 |
4 | 特開2023-052694 | 悪臭調節化合物の同定方法 | 2024-02-17 |
5 | 特開2022-187349 | 含硫化合物臭の抑制剤の探索方法 | 2024-02-17 |
6 | 特開2023-174085 | アンモニア臭の抑制剤の探索方法 | 2024-02-17 |
7 | 特表2021-506842 | ポリペプチドの放射性標識 | 2024-01-31 |
8 | 特表2022-548197 | 抗VEGFタンパク質組成物及びその製造方法 | 2024-01-15 |
9 | 特許7532752 | 改良されたウイルス検出方法 | 2023-11-06 |
10 | 特許7454002 | 収縮性バイオポリマー繊維の使用 | 2023-07-12 |
11 | 特表2021-503278 | CasZ組成物及び使用方法 | 2023-07-06 |
12 | 特表2020-528280 | シアリルトランスフェラーゼ及びシアリル化オリゴ糖の生産におけるその使用 | 2023-05-26 |
13 | 特許7411541 | カルバペネマーゼを産生性のエンテロバクター目、シュードモナス属、およびアシネトバクター属の種の、色原体を用いる検出 | 2023-02-28 |
14 | 特許7565801 | シアリル化糖の発酵産生 | 2023-02-17 |
15 | 特表2020-515255 | アルデヒドデヒドロゲナーゼバリアントおよび使用の方法 | 2022-11-01 |
16 | 特許7285780 | 誘導基質の非存在下における糸状菌細胞内でのタンパク質の産生 | 2022-09-09 |
17 | 特表2022-500069 | サイトカイン放出を刺激しうる新規ペプチド及びその誘導体 | 2022-09-06 |
18 | 特許7152399 | 悪臭中和剤を同定するための方法 | 2022-07-26 |
19 | 特許7475341 | 抗ヒトPD-1抗体結晶およびその使用方法 | 2022-07-25 |
20 | 特表2021-535221 | 新規精製方法 | 2022-04-20 |
Of the patent applications filed in the last 10 years (2014-11-01 to 2024-10-31), 39 patents/patent applications were protest more than once in the examination process of other patent applications. The mean of the number of protest is 1.2. The most protest patent is 特許6426567 "クリーンな味を産み出す酵素調製物" (3 times) , and the next most protest patent is 特許6904707 "ヒト化プログラム細胞死1遺伝子を持つ非ヒト動物" (3 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許6426567 | クリーンな味を産み出す酵素調製物 | 3 times |
2 | 特許6904707 | ヒト化プログラム細胞死1遺伝子を持つ非ヒト動物 | 3 times |
3 | 特許7152399 | 悪臭中和剤を同定するための方法 | 2 times |
4 | 特表2022-548197 | 抗VEGFタンパク質組成物及びその製造方法 | 2 times |
5 | 特表2021-506842 | ポリペプチドの放射性標識 | 2 times |
In the last 3 years (2021-11-01 ~ 2024-10-31), there were 262 patents Inspection from third parties. The average number of Inspection is 1.1 times. The most recently Inspection patent is 特表2022-519570 "安定化Fc融合タンパク質溶液" (Inspection day 2024-09-19) , next is 特表2021-517895 "HPV関連疾患を処置するための方法" (Inspection day 2024-09-19) .
- | No. | Title | Inspection days |
---|---|---|---|
1 | 特表2022-519570 | 安定化Fc融合タンパク質溶液 | 2024-09-19 |
2 | 特表2021-517895 | HPV関連疾患を処置するための方法 | 2024-09-19 |
3 | 特表2022-514618 | PD-L1に特異的な二環式ペプチドリガンド | 2024-09-18 |
4 | 特開2022-187349 | 含硫化合物臭の抑制剤の探索方法 | 2024-09-18 |
5 | 特開2023-174085 | アンモニア臭の抑制剤の探索方法 | 2024-09-18 |
6 | 特表2021-530212 | レトロトランスポゾンベースの送達媒体及びその使用方法 | 2024-09-10 |
7 | 特許6738314 | BCMAおよびCD3に対する結合分子 | 2024-09-10 |
8 | 特表2022-500042 | 抗HIV抗体10−1074バリアント | 2024-09-06 |
9 | 特表2022-514255 | PSMAに特異的な二環式ペプチドリガンド | 2024-09-05 |
10 | 特開2023-071635 | 分子標的薬nCoVshRNA・2ACE2の合成方法 | 2024-09-05 |
11 | 特表2022-537670 | CA2の組成物および調整可能な制御方法 | 2024-09-05 |
12 | 特表2022-544053 | 非枯渇性B細胞阻害剤によって免疫原性を低下させるための方法および組成物 | 2024-08-14 |
13 | 特表2023-548848 | ループスを処置するための方法および組成物 | 2024-08-14 |
14 | 特表2021-532135 | 標的細胞特異的な細胞質侵入抗原結合分子 | 2024-08-06 |
15 | 特表2022-501325 | 改変された抗体可変領域を含む抗原結合分子 | 2024-08-06 |
16 | 特表2023-503046 | ポンペ病およびリソソーム障害を処置するための肝臓特異的プロモーターを含む治療用アデノ随伴ウイルス | 2024-08-02 |
17 | 特表2021-514661 | サイトカインに連結させたECM親和性ペプチドを用いてがんを処置するための方法および組成物 | 2024-07-30 |
18 | 特表2020-532492 | カテコラミン誘発性多形性心室頻拍を治療または予防するための組成物および方法 | 2024-07-11 |
19 | 特開2022-081616 | TUSC2免疫療法のための方法および組成物 | 2024-07-11 |
20 | 特表2022-513223 | MT1-MMPに特異的な二環式ペプチドリガンド | 2024-07-10 |
Of the patent applications filed in the last 10 years (2014-11-01 to 2024-10-31), 473 patents/patent applications were inspection more than once in the examination process of other patent applications. The mean of the number of inspection is 1.1. The most inspection patent is 特開2016-155809 "狭窄病変および血栓溶解療法のための剪断による制御放出" (5 times) , and the next most inspection patent is 特表2023-506465 "抗MerTK抗体及びその使用方法" (5 times) .
- | No. | Title | |
---|---|---|---|
1 | 特開2016-155809 | 狭窄病変および血栓溶解療法のための剪断による制御放出 | 5 times |
2 | 特表2023-506465 | 抗MerTK抗体及びその使用方法 | 5 times |
3 | 特許6426567 | クリーンな味を産み出す酵素調製物 | 4 times |
4 | 特許6904707 | ヒト化プログラム細胞死1遺伝子を持つ非ヒト動物 | 4 times |
5 | 特許7292035 | アルカロイドレベル改変タバコ植物体及び製品を作出する組成物及び方法 | 3 times |
Of the patent applications filed in the last 10 years (2014-11-01 to 2024-10-31), 2,067 patents/patent applications were cited more than once in the examination process of other patent applications. The mean of the number of cited is 2.3. The most cited patent is 特許6232009 "CDRのアミノ酸置換により抗体の等電点を改変する方法" (39 times) , and the next most cited patent is 特許6778114 "イミド系タンパク質分解モジュレーター及び関連する使用方法" (32 times) .
- | No. | Title | |
---|---|---|---|
1 | 特許6232009 | CDRのアミノ酸置換により抗体の等電点を改変する方法 | 39 times |
2 | 特許6778114 | イミド系タンパク質分解モジュレーター及び関連する使用方法 | 32 times |
3 | 特許6352974 | ワクチンのための高力価組み換えインフルエンザ・ウィルス | 26 times |
4 | 特開2016-063824 | マイクロ流体システム内のインビトロ進化 | 25 times |
5 | 特許6375329 | ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス | 23 times |
"Patent Integration Report" is a web service provided by "Patent Integration Co., Ltd." operated by patent attorneys who are experts in intellectual property rights. Based on the latest patent data, this is one of the largest patent report services in Japan that provides information on technology trends in various companies and technology fields.
The purpose of this web service is to make intellectual property information familiar to many people, regardless of whether they have an interest in intellectual property rights, and to make use of it.
We actively provide various types of patent information that can be used in various media articles such as newspapers, magazines, and web media. Please feel free to contact us from "Inquiry form for details on the content of patent information that can be provided, conditions for provision, etc. Please contact us.
All rights related to the data, documents and charts belong to "an integrated patent search/analysis service provider, Patent Integration". Please specify the source “Patent Integration Report, URL: https://patent-i.com/report/en/" when inserting them into in-house materials, external report materials, etc., regardless of whether they are paid or free of charge.
Patent data is obtained by aggregating and analyzing the latest patent data issued by the Patent Offices of respective countries and jurisdictions and by WIPO. Although we take great care in publishing and analyzing the results, we do not guarantee the correctness of the data. We appreciate your understanding.
If you have any concerns about this service, please feel free to contact us.
All rights to the data, documents, figures and tables are reserved by e-Patent. When publishing internal documents, external reports, etc. (whether paid or free of charge), please use the following URL: https://e-patent.co.jp/.
e-Patent will not be liable for any damages or losses arising from the use of the global patent application status, ranking information, or population search formula in the "SDGs Global Company Ranking from a Patent Perspective". Items with ● in front of the target are not supported at this time (judged to be difficult to approach from the patent information analysis).
There is no problem to cite patent application status and ranking information, but please clearly indicate "Source: e-Patent Co.
Credit notation
・MeCab user dictionary for science technology term © National Bioscience Database Center licensed under CC Attribution-Share Alike 4.0 International